Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics – statnews.com

Home
What's the word?
Test your knowledge with our new weekday mini crossword
By Brittany Trang
June 3, 2026
Health Tech Reporter
Brittany Trang
Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter. Follow her on Threads, Mastodon, and Bluesky. You can reach Brittany on Signal at btrang.01.
Jakob Uszkoreit went from inventing the “T” in ChatGPT to putting the “AI” in Alnylam’s RNAi therapeutics.
After over a dozen years at Google, where he’d co-authored the seminal “Attention is all you need” paper that laid the foundations for artificial intelligence models like GPT, Uszkoreit in 2021 left a job at Google Brain to start Inceptive Nucleics. The company is building “AI foundation models of life” — models that will hopefully learn so much about how biology operates that they will be reusable across many different tasks without having to be trained specifically to do them. 
Advertisement
On Wednesday, Alnylam and Inceptive announced a new, three-year strategic collaboration worth up to $2 billion, with $30 million up front in cash and equity in the startup. The additional payments will be predicated on the co-discovered drugs achieving preclinical, regulatory, and commercial sales milestones. In 2025, Alnylam’s total revenues were $3.7 billion. 
STAT+ Exclusive Story
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
Brittany Trang
Health Tech Reporter
Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be harmed? She writes the weekly AI Prognosis newsletter. Follow her on Threads, Mastodon, and Bluesky. You can reach Brittany on Signal at btrang.01.
Your morning rundown of the science, politics, and money driving biotech today
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
By Elaine Chen
By Allison DeAngelis
Advertisement
By Elaine Chen
By Elaine Chen
By Adam Feuerstein, Matthew Herper, Angus Chen, and Katherine MacPhail

By Adam Feuerstein

By Adam Feuerstein

By Katie Palmer

By Mario Aguilar

By Sarah Todd
Share options
X
Bluesky
LinkedIn
Facebook
Doximity
Copy link
Reprints
A decade of reporting from the frontiers of health and medicine
Company
Account
More

source